Sun Pharma Advanced Research Company Limited reported a consolidated net profit of ₹1,55,320.43 lakh for the financial year ended March 31, 2026, compared to a net loss of ₹34,250.94 lakh in the previous year. The turnaround was primarily driven by the recognition of income from a Priority Review Voucher (PRV) granted by the USFDA, which was subsequently sold for USD 195 million.

The company’s total income for the year stood at ₹1,88,999.95 lakh, a significant increase from ₹7,355.71 lakh in the previous year. This rise was largely due to the recognition of ₹1,84,002 lakh in respect of the PRV granted on February 03, 2026, for the drug Sezaby®. The PRV, accounted for as a non-monetary government grant under Ind AS 20, was sold on April 30, 2026.

Financial Performance

The consolidated financial results for the year ended March 31, 2026, show a marked improvement in the company’s bottom line. Total revenue from operations was ₹1,87,916.83 lakh, up from ₹7,176.60 lakh in the previous year. The profit before tax for the year was ₹1,55,300.99 lakh, compared to a loss before tax of ₹34,278.12 lakh in the previous year.

The board has not recommended any dividend for the financial year under review.

Corporate Developments

During the year, the company’s board approved a preferential issue of up to 3,85,10,000 warrants to Shanghvi Finance Private Limited, a promoter group entity. The warrants were allotted on May 19, 2026, at an issue price of ₹155.80 per warrant, aggregating to ₹5,99,98,58,000. The company received 25% of the issue price, amounting to ₹1,49,99,64,500, at the time of allotment.

The board also approved the SPARC Employees Stock Option Scheme 2026, though no stock options were granted during the year.

Strategic Focus

The company stated that its strategy is anchored on a differentiated, innovation-led approach. It continues to focus its research and development efforts on oncology and immunology, leveraging advanced modalities such as Antibody Drug Conjugates (ADCs) and CAR-T therapies. The company is also advancing its pipeline in dermatology and autoimmune disorders.

Sun Pharma Advanced Research Company Ltd has appointed Anil Raghavan as Managing Director and Chief Executive Officer effective August 11, 2026, subject to shareholder approval. The Board of Directors approved the appointment during a meeting held on July 13, 2026. Raghavan, currently the Chief Executive Officer of the company, will assume the new role immediately following the retirement of the incumbent director.

Leadership Transition

Dr. Rajamannar Thennati will retire from the Board of Directors upon completion of his term as a Director at the ensuing 21st Annual General Meeting scheduled for August 10, 2026. The company stated that Raghavan is not related to any other director and is not debarred from holding the office of director by any SEBI order or other authority.

The following table summarises the key management changes:

Profile of the Incoming MD & CEO

Raghavan is responsible for developing and executing strategies to realize the company's vision of becoming a global pharmaceutical leader. He operates from the company's Mumbai office. Additionally, he serves as a mentor at AIRAMATRIX Private Limited, an early-stage Machine Learning company focusing on high content image processing and deep learning for drug development and clinical practice.

Prior to his current role, Raghavan spent a decade consulting with leading firms such as Arthur Andersen, KPMG, and Cambridge Technology Partners. He assisted leadership teams in various sectors, including Media and Entertainment, Telecommunications, and Health Care services, in developing business strategies and improving performance. He is an Industrial Engineer and an active speaker at industry events.

Regulatory Disclosures

The disclosures were made to the National Stock Exchange of India Ltd. and BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kajal Damania, Company Secretary and Compliance Officer, signed the regulatory filing.